Adlai Nortye (ANL) Competitors $1.67 -0.02 (-1.42%) Closing price 08/22/2025 03:57 PM EasternExtended Trading$1.65 -0.02 (-0.96%) As of 08/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. HUMA, ANNX, GALT, SCPH, SOPH, EDIT, TKNO, ALLO, TVRD, and GNFTShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Humacyte (HUMA), Annexon (ANNX), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), SOPHiA GENETICS (SOPH), Editas Medicine (EDIT), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Humacyte Annexon Galectin Therapeutics scPharmaceuticals SOPHiA GENETICS Editas Medicine Alpha Teknova Allogene Therapeutics Tvardi Therapeutics GENFIT Adlai Nortye (NASDAQ:ANL) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Does the media favor ANL or HUMA? In the previous week, Humacyte had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 10 mentions for Humacyte and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.94 beat Humacyte's score of -0.56 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Humacyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has higher valuation and earnings, ANL or HUMA? Adlai Nortye has higher revenue and earnings than Humacyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M12.30-$51.87MN/AN/AHumacyte$1.57M159.38-$148.70M-$0.45-3.51 Do analysts prefer ANL or HUMA? Adlai Nortye currently has a consensus target price of $9.00, suggesting a potential upside of 440.22%. Humacyte has a consensus target price of $10.64, suggesting a potential upside of 573.60%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ANL or HUMA more profitable? Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Humacyte N/A N/A -78.26% Do insiders & institutionals have more ownership in ANL or HUMA? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 5.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, ANL or HUMA? Adlai Nortye has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. SummaryHumacyte beats Adlai Nortye on 9 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.48M$3.11B$5.83B$9.74BDividend YieldN/A2.24%4.40%4.10%P/E RatioN/A21.4031.4326.05Price / Sales12.30395.34469.65121.10Price / CashN/A43.2325.7828.78Price / Book2.419.879.526.07Net Income-$51.87M-$54.06M$3.26B$265.39M7 Day Performance-5.93%1.60%1.37%1.56%1 Month Performance15.69%3.20%2.97%0.48%1 Year Performance-44.28%10.82%30.23%18.88% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.69 of 5 stars$1.67-1.4%$9.00+440.2%-44.3%$61.48M$5M0.00127Positive NewsGap DownHUMAHumacyte2.1146 of 5 stars$1.60-11.4%$10.64+567.3%-77.5%$247.42M$1.57M-3.54150High Trading VolumeANNXAnnexon2.9746 of 5 stars$2.19-6.8%$12.50+470.8%-60.8%$240.27MN/A-1.7060GALTGalectin Therapeutics2.3933 of 5 stars$3.75-3.8%$6.00+60.0%+77.5%$240.23MN/A-5.869SCPHscPharmaceuticals4.5333 of 5 stars$4.46-6.7%$14.00+213.9%-9.7%$237.71M$49.97M-2.4630News CoveragePositive NewsTrading HaltedSOPHSOPHiA GENETICS2.9309 of 5 stars$3.51+0.6%$8.00+127.9%-3.5%$237.21M$65.17M-7.98520Positive NewsEDITEditas Medicine4.0574 of 5 stars$2.63-3.7%$5.10+93.9%-27.6%$236.49M$38.90M-0.92230TKNOAlpha Teknova1.6526 of 5 stars$4.41flat$10.00+126.8%-4.8%$235.98M$37.74M-10.50240ALLOAllogene Therapeutics2.6357 of 5 stars$1.05-3.7%$8.44+704.2%-54.4%$232.97M$20K-0.95310TVRDTvardi TherapeuticsN/A$24.67-0.3%$64.25+160.4%N/A$230.91M$7.14M0.0080News CoverageGNFTGENFIT2.1418 of 5 stars$4.48-0.4%$9.00+100.9%-0.8%$224.01M$67.00M0.00120Positive NewsGap Up Related Companies and Tools Related Companies Humacyte Alternatives Annexon Alternatives Galectin Therapeutics Alternatives scPharmaceuticals Alternatives SOPHiA GENETICS Alternatives Editas Medicine Alternatives Alpha Teknova Alternatives Allogene Therapeutics Alternatives Tvardi Therapeutics Alternatives GENFIT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access